However, MDS patients with both, SF3B1 mutations and del(5q), exhibit immunophenotypic features more consistent with isolated del(5q) MDS, with decreased numbers of erythroid progenitors, higher CD71 expression and lower CD71 CV, suggesting that these patients may gain benefit from lenalidomide, rather than from luspatercept as first-line treatment (168). This evidence concerns the gene SF3B1 and myelodysplastic syndrome.